Morphic Medical Welcomes New Leadership to Propel Growth for Diabetes Treatment

Morphic Medical, known for pioneering the world's first medical device targeting the root causes of type 2 diabetes, has made notable additions to its board of directors. Dr. Terri Cooper has been appointed as the Chair of the Board, providing strategic oversight during an exciting phase for the company. Joining her is Craig Richardson, who will serve as a Non-Executive Board Member, both effective immediately.

Key Appointments to Enhance Strategic Direction

These leadership changes occur in the wake of the successful CE Mark approval of Morphic's innovative RESET technology, which is designed to address obesity and its associated metabolic diseases. The company continues to expand its operations within Europe while gearing up for greater accessibility across international markets.

As the new Chair, Dr. Cooper brings a wealth of experience and strategic acumen that are crucial for Morphic Medical as it navigates this pivotal growth stage. She has a proven track record in building successful healthcare businesses, positioning her perfectly to guide the company forward. Dr. Cooper emphasized the importance of Morphic's unique technology, which has shown the potential to reshape treatment pathways in metabolic diseases. She stated, "Having achieved significant clinical, regulatory, and commercial milestones, the Company is well positioned for its next stage of growth. I look forward to working with the Board and executive team as we advance toward becoming a leading global metabolic health company."

Craig Richardson’s wealth of knowledge in health economics and market access will also be pivotal. His capacity to articulate the clinical and economic advantages of the RESET therapy will support Morphic's ongoing engagements with payers, providers, and policymakers, enhancing patient access to the innovative treatment. Richardson remarked, "With the global burden of obesity and type 2 diabetes escalating, it is vital for innovative therapies to prove their clinical efficacy and economic viability. RESET® offers the promise of substantial patient benefits while also aiming to reduce long-term healthcare expenditures."

Building a Strengthened Foundation for the Future

Morphic’s CEO, Mike Gutteridge, expressed his gratitude towards former Chair Mark Lerdal for his invaluable contributions to the company. Gutteridge remarked, "We warmly welcome Dr. Cooper and Craig to our Board of Directors. Their experiences in the healthcare space not only enrich our board but will also uphold our commitment to enhancing the lives of patients battling obesity and type 2 diabetes."

These recent appointments symbolize Morphic Medical's unwavering goal to construct a world-class governance structure that will underpin its strategic ambitions. As the company intends to broaden its commercial strategy and international reach, both Dr. Cooper and Mr. Richardson's leadership will play a crucial role in achieving Morphic Medical's long-term mission of improving outcomes for patients suffering from obesity and type 2 diabetes.

About Morphic Medical

Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical is dedicated to tackling the serious health challenges posed by obesity and metabolic diseases. The company developed RESET, a groundbreaking endoscopically delivered therapy providing a non-surgical solution for morbid obesity or when obesity is present alongside other cardiometabolic risk factors. RESET is currently approved for sale in the EU and UK, and is only available for investigational use in the U.S. For further details, please visit their official website at morphicmedical.com or follow them on Twitter and LinkedIn.